Key facts
- It has raised $10.0M; the latest was Seed Round ($10.0M) in Oct 2025.
- Notable investors include Wa'ed Ventures, Qomel.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Kure Cells
- ·The full record, as it builds
Funding rounds
No funding rounds for Kure Cells are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Kure Cells
Operator of a biotechnology company intended to make transformative cell therapy treatments more accessible, faster and cost-effective for patients worldwide. The company's platform offers same-day engineering of a patient's T-cells to fight cancer, enabling customers to receive next-generation CAR-T and cell-based oncology therapies with significantly reduced multi-week manufacturing wait times and lower costs.
- Sector
- Healthcare
- Founded
- 2021
- Website
- kurecells.bio/
- Ownership
- Privately Held (backing)
Kure Cells doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Kure Cells shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Kure Cells in its N-PORT filings yet. We sweep new filings monthly.